IceCure Medical Future Growth
Future criteria checks 5/6
IceCure Medical is forecast to grow earnings and revenue by 53.4% and 57.1% per annum respectively while EPS is expected to grow by 56.2% per annum.
Key information
53.4%
Earnings growth rate
56.2%
EPS growth rate
| Medical Equipment earnings growth | 17.0% |
| Revenue growth rate | 57.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Nov 2024 |
Recent future growth updates
Recent updates
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth?
Jul 31
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
Nov 29Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?
Aug 08IceCure gains 19% on seeking FDA nod for cancer treatment
Oct 19IceCure files application for approval of ProSense in Canada for tumors
Jul 25IceCure Medical: Advancing Cryotherapy For Cancer Treatment
Jan 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 21 | -7 | -11 | N/A | 2 |
| 12/31/2025 | 8 | -14 | -13 | N/A | 3 |
| 12/31/2024 | 3 | -14 | -15 | N/A | 3 |
| 9/30/2024 | 4 | -14 | -11 | -11 | N/A |
| 6/30/2024 | 3 | -14 | -11 | -11 | N/A |
| 3/31/2024 | 3 | -14 | -13 | -12 | N/A |
| 12/31/2023 | 3 | -15 | -13 | -13 | N/A |
| 9/30/2023 | 3 | -16 | -15 | -14 | N/A |
| 6/30/2023 | 3 | -16 | -15 | -14 | N/A |
| 3/31/2023 | 3 | -16 | -15 | -14 | N/A |
| 12/31/2022 | 3 | -17 | -15 | -14 | N/A |
| 9/30/2022 | 4 | -16 | -17 | -16 | N/A |
| 6/30/2022 | 4 | -15 | -17 | -16 | N/A |
| 3/31/2022 | 3 | -13 | -14 | -14 | N/A |
| 12/31/2021 | 4 | -10 | -13 | -13 | N/A |
| 9/30/2021 | 4 | -8 | -9 | -8 | N/A |
| 6/30/2021 | 4 | -6 | -7 | -6 | N/A |
| 3/31/2021 | 4 | -4 | -5 | -5 | N/A |
| 12/31/2020 | 4 | -4 | -4 | -4 | N/A |
| 9/30/2020 | 3 | -4 | -2 | -2 | N/A |
| 6/30/2020 | 3 | -4 | -1 | 0 | N/A |
| 3/31/2020 | 2 | -4 | -1 | -1 | N/A |
| 12/31/2019 | 2 | -5 | -2 | -2 | N/A |
| 9/30/2019 | 1 | -5 | N/A | N/A | N/A |
| 6/30/2019 | 1 | -4 | -4 | -4 | N/A |
| 3/31/2019 | 1 | -4 | -4 | -4 | N/A |
| 12/31/2018 | 1 | -4 | -3 | -3 | N/A |
| 9/30/2018 | 1 | -3 | N/A | N/A | N/A |
| 6/30/2018 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2018 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2017 | 1 | -3 | N/A | -3 | N/A |
| 12/31/2016 | 1 | -3 | N/A | -3 | N/A |
| 9/30/2016 | 1 | -3 | N/A | -3 | N/A |
| 6/30/2016 | 1 | -4 | N/A | -4 | N/A |
| 3/31/2016 | 1 | -4 | N/A | -3 | N/A |
| 12/31/2015 | 1 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 1 | -4 | N/A | -3 | N/A |
| 6/30/2015 | 1 | -4 | N/A | -3 | N/A |
| 3/31/2015 | 1 | -4 | N/A | -3 | N/A |
| 12/31/2014 | 1 | -5 | N/A | -3 | N/A |
| 9/30/2014 | 1 | -5 | N/A | -4 | N/A |
| 6/30/2014 | 1 | -5 | N/A | -4 | N/A |
| 3/31/2014 | 0 | -5 | N/A | -3 | N/A |
| 12/31/2013 | 0 | -5 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICCM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: ICCM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICCM is expected to become profitable in the next 3 years.
Revenue vs Market: ICCM's revenue (57.1% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: ICCM's revenue (57.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICCM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 19:36 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IceCure Medical Ltd is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Yi Chen | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |